Biodesix (BDSX) | Financial Analysis & Statements
Biodesix Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
28.8M
Gross Profit
23.9M
83.03%
Operating Income
-2.0M
-6.84%
Net Income
-4.0M
-13.84%
EPS (Diluted)
$-0.49
Balance Sheet Metrics
Total Assets
87.5M
Total Liabilities
89.9M
Shareholders Equity
-2.5M
Cash Flow Metrics
Operating Cash Flow
-247.0K
Free Cash Flow
674.0K
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Biodesix Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 88.5M | 71.3M | 49.1M | 38.2M | 54.5M |
| Cost of Goods Sold | 16.7M | 15.6M | 13.0M | 14.2M | 30.5M |
| Gross Profit | 71.8M | 55.8M | 36.1M | 24.1M | 24.0M |
| Gross Margin % | 81.1% | 78.2% | 73.5% | 63.0% | 44.0% |
| Operating Expenses | |||||
| Research & Development | 12.0M | 9.6M | 10.0M | 13.1M | 12.8M |
| Selling, General & Administrative | 87.5M | 80.5M | 67.4M | 61.5M | 50.5M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 99.5M | 90.0M | 77.4M | 74.6M | 63.3M |
| Operating Income | -27.8M | -34.3M | -41.3M | -50.5M | -39.3M |
| Operating Margin % | -31.4% | -48.0% | -84.1% | -132.2% | -72.1% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 7.7M | 8.3M | 9.5M | 8.1M | 4.5M |
| Other Non-Operating Income | 217.0K | -413.0K | -1.3M | -6.9M | 667.0K |
| Pre-tax Income | -35.3M | -42.9M | -52.1M | -65.4M | -43.2M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -35.3M | -42.9M | -52.1M | -65.4M | -43.2M |
| Net Margin % | -39.8% | -60.2% | -106.2% | -171.3% | -79.2% |
| Key Metrics | |||||
| EBITDA | -21.6M | -28.7M | -35.8M | -44.6M | -36.1M |
| EPS (Basic) | - | $-6.60 | $-0.64 | $-1.55 | $-1.58 |
| EPS (Diluted) | - | $-6.60 | $-0.64 | $-1.55 | $-1.58 |
| Basic Shares Outstanding | - | 6483500 | 82113000 | 42103000 | 27365000 |
| Diluted Shares Outstanding | - | 6483500 | 82113000 | 42103000 | 27365000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Biodesix Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 19.0M | 26.2M | 26.3M | 43.1M | 32.7M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 9.0M | 8.6M | 7.7M | 5.1M | 3.7M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 4.5M | 4.6M | 5.7M | 5.2M | 7.2M |
| Total Current Assets | 32.5M | 39.5M | 39.7M | 53.3M | 43.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 9.4M | 7.6M | 7.8M | 9.0M | 6.8M |
| Goodwill | 33.9M | 35.9M | 38.0M | 39.9M | 41.7M |
| Intangible Assets | 3.9M | 5.9M | 7.9M | 9.8M | 11.6M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 8.2M | 7.3M | 6.9M | 5.9M | 1.7M |
| Total Non-Current Assets | 55.0M | 57.8M | 59.4M | 39.6M | 32.5M |
| Total Assets | 87.5M | 97.2M | 99.1M | 92.9M | 76.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.1M | 2.2M | 2.9M | 1.7M | 1.7M |
| Short-term Debt | 1.4M | 740.0K | 303.0K | 1.6M | 19.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 992.0K | 641.0K | 22.2M | 10.4M | 17.8M |
| Total Current Liabilities | 17.4M | 14.3M | 33.4M | 22.8M | 29.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 71.5M | 61.2M | 60.4M | 30.3M | 10.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 1.0M | 815.0K | 712.0K | 19.2M | 17.4M |
| Total Non-Current Liabilities | 72.5M | 62.1M | 61.1M | 49.5M | 27.4M |
| Total Liabilities | 89.9M | 76.4M | 94.5M | 72.3M | 56.4M |
| Equity | |||||
| Common Stock | 8.0K | 145.0K | 96.0K | 78.0K | 31.0K |
| Retained Earnings | -497.8M | -462.5M | -419.6M | -367.4M | -302.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -2.5M | 20.9M | 4.6M | 20.6M | 19.7M |
| Key Metrics | |||||
| Total Debt | 72.9M | 62.0M | 60.7M | 31.8M | 10.0M |
| Working Capital | 15.1M | 25.2M | 6.3M | 30.5M | 14.7M |
Balance Sheet Composition
Biodesix Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -35.3M | -42.9M | -52.1M | -65.4M | -43.2M |
| Depreciation & Amortization | 5.6M | 5.5M | 5.5M | 5.8M | 3.2M |
| Stock-Based Compensation | 4.1M | 6.6M | 5.4M | 6.0M | 4.9M |
| Working Capital Changes | -1.5M | -23.3M | -7.5M | -6.0M | 12.0M |
| Operating Cash Flow | -25.7M | -51.7M | -25.2M | -51.3M | -18.7M |
| Investing Activities | |||||
| Capital Expenditures | -259.0K | -3.2M | -22.9M | -3.3M | -2.2M |
| Acquisitions | - | - | - | - | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -259.0K | -3.2M | -22.9M | -3.3M | -2.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 10.0M | 0 | 10.0M | 45.1M | 30.1M |
| Debt Repayment | -21.0K | -51.0K | -49.0K | -28.6M | -45.4M |
| Financing Cash Flow | 15.9M | 51.4M | 28.4M | 58.3M | 165.0K |
| Free Cash Flow | -23.7M | -52.1M | -45.9M | -48.5M | -30.8M |
| Net Change in Cash | -10.0M | -3.5M | -19.7M | 3.7M | -20.8M |
Cash Flow Trend
Biodesix Key Financial Ratios
Valuation Ratios
Forward P/E
-47.73
Price to Book
-34.62
Price to Sales
1.20
PEG Ratio
-47.73
Profitability Ratios
Profit Margin
-39.85%
Operating Margin
-6.84%
Return on Equity
-383.09%
Return on Assets
-18.79%
Financial Health
Current Ratio
1.86
Debt to Equity
-30.44
Beta
0.57
Per Share Data
EPS (TTM)
$-4.67
Book Value per Share
$-0.30
Revenue per Share
$11.72
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BDSX | 107.5M | - | -34.62 | -383.09% | -39.85% | -30.44 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Burning Rock Biotech | 221.7M | -0.61 | 2.76 | -9.92% | -10.26% | 8.06 |
| Fonar | 118.6M | 16.35 | 0.70 | 6.01% | 7.13% | 24.44 |
| Oncocyte | 65.6M | -0.81 | 109.66 | 496.38% | 39.34% | 3.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.





